Meeting
2015 Gastrointestinal Cancers Symposium
Gastrointestinal organoid cultures for functional evaluation of oncogenic loci.
Authors
Ameen Abdulla Salahudeen
Stanford University, Stanford, CA
Ameen Abdulla Salahudeen , Xingnan Li , Michael Cantrell , Calvin Jay Kuo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 85)
DOI
10.1200/jco.2015.33.3_suppl.85
Abstract #
85
Poster Bd #
B35
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
First Author: Sean Matthew McBride
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).
First Author: Tamim Niazi
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk of biochemical recurrence (BCR) after radical prostatectomy (RP) in the ongoing phase 3 PRIMORDIUM study.
First Author: Boris A. Hadaschik